Mazdutide Clinical Trials (2026): 6 Studies for Type 2 Diabetes & Dementia, Mild
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
6 Mazdutide clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 6 indications (including Type 2 Diabetes & Dementia, Mild) and 2,366 total planned enrollment. 2 Phase 3 Mazdutide trials and 1 Phase 2 are listed. 5 Mazdutide clinical trials are actively recruiting. Most recent activity: NCT07135141 (Sep 2029).
Mazdutide clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | not yet recruiting | Total |
|---|---|---|---|---|
| P1/P2 | 1 | 1 | ||
| P2 | 1 | 1 | ||
| P3 | 1 | 1 | 2 | |
| N/A | 1 | 1 | 2 |
Recruiting Mazdutide clinical trials (5)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07135141 | SMARTMazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity | N/A | Severe Obesity | 256 | Sep 2025 |
| NCT07083154 | GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study) | P3 | Dementia, Mild | 420 | Sep 2025 |
| NCT07517042 | ASCEND-1ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management | N/A | Obesity | 420 | Apr 2026 |
| NCT07417306 | SGLT2A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | P3 | Type 2 Diabetes | 912 | Mar 2026 |
| NCT06519656 | Efficacy of Mazdutide for Treating PCOS | P1/P2 | Polycystic Ovary Syndrome | 50 | Oct 2024 |
Mazdutide clinical trials by indication
Obesity (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07517042 | ASCEND-1 | N/A | recruiting | ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management |
Type 2 Diabetes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07417306 | SGLT2 | P3 | not yet recruiting | A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor |
Severe Obesity (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07135141 | SMART | N/A | not yet recruiting | Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity |
Dementia, Mild (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07083154 | — | P3 | recruiting | GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study) |
Alcohol Use Disorder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06817356 | — | P2 | completed | A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder |
Polycystic Ovary Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06519656 | — | P1/P2 | recruiting | Efficacy of Mazdutide for Treating PCOS |
Mazdutide pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SGLT2 | NCT07417306 | P3 | not yet recruiting | Type 2 Diabetes | 912 | — |
All Mazdutide trials (6)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07135141 | SMART | Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity | N/A | not yet recruiting | 256 | Beijing Friendship Hospital | Sep 2025 |
| NCT07083154 | GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study) | P3 | recruiting | 420 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Sep 2025 | |
| NCT07517042 | ASCEND-1 | ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management | N/A | recruiting | 420 | Shanghai Zhongshan Hospital | Apr 2026 |
| NCT07417306 | SGLT2 | A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | P3 | not yet recruiting | 912 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Mar 2026 |
| NCT06519656 | Efficacy of Mazdutide for Treating PCOS | P1/P2 | recruiting | 50 | Shanghai Zhongshan Hospital | Oct 2024 | |
| NCT06817356 | A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder | P2 | completed | 308 | Eli Lilly and Company | Feb 2025 |
Mazdutide clinical trials: frequently asked questions
- How many Mazdutide clinical trials are there?
- 6 Mazdutide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 1 is marked completed.
- Are Mazdutide clinical trials recruiting in 2026?
- Yes — 3 Mazdutide trials are actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is Mazdutide being studied for?
- Mazdutide is being studied for Type 2 Diabetes, Dementia, Mild, Mild Cognitive Impairment, Obesity, Polycystic Ovary Syndrome and 3 more. The trials are grouped by indication on this page.
- What phase is Mazdutide in?
- Mazdutide clinical trials span 2 Phase 3, 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Mazdutide clinical trials?
- The lead sponsor across the most Mazdutide trials is Shanghai Zhongshan Hospital, with 4 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Mazdutideas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: